- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05176041
SLE Therapy Changes in Pregnancy and Relation to Pregnancy Outcome
December 28, 2021 updated by: Naser Al-Husban, University of Jordan
Therapeutic Alterations of Systemic Lupus Erythematosus (SLE) Patients in Pregnancy and Feto-maternal Outcomes; Retrospective Cohort Study
to review the changes to SLE medications during pregnancy including adherence and non-adherence to the medications and correlate these to the pregnancy outcome and post-partum course of the disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This was a retrospective study of pregnancies in SLE patients.
These patients had confirmed SLE diagnosis according to the American College of Rheumatology (ACR) criteria (5).
The diagnosis of SLE was confirmed by consultant rheumatologist.
These patients were followed up by consultant rheumatologist and obstetrician.
The pregnancies' data were curated using the patients' medical files and notes, both paper-based and electronic, antenatal records, rheumatology and hematology clinic notes in addition to delivery and postpartum records.
These data were collected including ID numbers, ages, duration of the SLE, their SLE medications before the pregnancy (names, doses and frequency) and whether the SLE was active or not in the 6 months prior to the pregnancy using systemic lupus erythematosus disease activity index (SLEDAI) score.
the investigators studied Hydroxychloroquine (HCQ), prednisolone and anti-coagulants (low-dose acetylsalicylic acid; 100 mg orally once daily and low molecular weight heparins (LMWH) Enoxaparin 40 mg subcutaneously once daily) as these were the most commonly used medications.
The use of these medications in the different pregnancy periods were noted and analyzed (BPG, before pregnancy; DPG, during pregnancy; PG, pregnancy; PP, post-partum).
Changes in these medications were also recorded.
The data was then analyzed to find out the rates of changes and discontinuation.
The postpartum period was also studied similarly.
The investigators correlated these alterations to the following feto-maternal outcomes; miscarriage, preterm delivery, intra-uterine growth restriction (IUGR) and intra-uterine fetal death (IUFD).
The 6 months-pre-conceptual SLEDAI score was recorded and investigated in relation to the above mentioned feto-maternal outcomes and postpartum relapse.
We divided the pregnancies into 2 groups; Group A, inactive SLE and SLEDAI score of 0-3; Group b, active SLE and SLEDAI score of 4-24.
Study Type
Observational
Enrollment (Actual)
156
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 49 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Pregnant women with SLE
Description
Inclusion Criteria:
- confirmed SLE
- completed data
Exclusion Criteria:
- doubtful diagnosis of SLE
- those with missing data
- those with medications other than prednisolone, HCQ and anticoagulants
- those with multifetal pregnancies
- those patients with confirmed other medical diseases including diabetes mellitus, hypertension, thyroid disorders, anti-phospholipid antibody syndrome (APAS), cardiac disease
- those with confirmed deep vein thrombosis (DVT) or pulmonary embolism (PE)
- those with associated hematological diseases including SLE-associated thrombocytopenia.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
fetal growth restriction
Time Frame: 8 months
|
the effects of changes in SLE medications in pregnancy periods on final new born weight in grams.
|
8 months
|
development of pre-eclampsia
Time Frame: 6 months
|
SLE medication change and its effects on risk of pre-eclampsia
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Naser Al-Husban, A. Professor, The University of Jordan
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2016
Primary Completion (Actual)
November 1, 2020
Study Completion (Actual)
January 1, 2021
Study Registration Dates
First Submitted
December 5, 2021
First Submitted That Met QC Criteria
December 28, 2021
First Posted (Actual)
January 4, 2022
Study Record Updates
Last Update Posted (Actual)
January 4, 2022
Last Update Submitted That Met QC Criteria
December 28, 2021
Last Verified
December 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- the Jordan University hospital
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
available on reasonable request
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fetal Growth Retardation
-
amera mohamedUnknownThe Relationship Between Second Trimester Placental Growth Factor Level and Fetal Growth RestrictionIntra Uterine Growth RetardationEgypt
-
Johns Hopkins UniversityWithdrawnFetal Growth Retardation | Intrauterine Growth Restriction | Intrauterine Growth Retardation | Fetal Growth Restriction
-
Nantes University HospitalTerminatedIntra Uterine Growth RetardationFrance
-
Poitiers University HospitalCompletedIntrauterine Growth Retardation (IUGR)France
-
PfizerCompletedGrowth Disorders | Intrauterine Growth RetardationFrance
-
Van Bölge Eğitim ve Araştırma HastanesiCompletedIntrauterine RetardationTurkey
-
Ain Shams Maternity HospitalCompletedFasting | Fetal Growth Retardation, Antenatal (Disorder)
-
Merck KGaA, Darmstadt, GermanyMerck Serono S.A., GenevaCompletedChildren Born With Serious Intra-uterine Growth Retardation
-
University Hospital, GrenobleRegistre de Handicap de l'Enfant et Observatoire Périnatal (RHEOP) Isère,... and other collaboratorsUnknownStillbirth | Infant, Small for Gestational Age | Intrauterine Growth RetardationFrance
-
University of South FloridaCompleted
Clinical Trials on Naser Al-Husban
-
University of JordanAysha Alkhayat; Mariam Aljweesri; Reem Alharbi; Zahraa AljazzafCompleted
-
University of JordanCompletedHysteroscopic Metroplasty and Myomectomy
-
University of JordanCompleted
-
Alcon ResearchWithdrawn
-
Alios Biopharma Inc.Completed
-
Hospital General Universitario ElcheUnknown
-
Alcon ResearchCompleted
-
Alcon ResearchCompleted